Open Access

Combination of azithromycin and methylprednisolone alleviates Mycoplasma pneumoniae induced pneumonia by regulating miR‑499a‑5p/STAT3 axis

  • Authors:
    • Yongli Chen
    • Shanwu Dong
    • Lin Tian
    • Haishan Chen
    • Jing Chen
    • Chunzhi He
  • View Affiliations

  • Published online on: July 19, 2022     https://doi.org/10.3892/etm.2022.11515
  • Article Number: 578
  • Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Mycoplasma pneumoniae (M. pneumoniae) is a contributing factor to community‑acquired pneumonia in children. The present study sought to explain the underlying mechanism of azithromycin (AZM) combined with methylprednisolone (MP) in the treatment of M. pneumoniae infection. Peripheral blood samples were obtained from patients with M. pneumoniae and healthy volunteers for analysis. A549 cells were infected with M. pneumoniae to construct an in vitro cell model with M. pneumoniae, followed by treatment with AZM and MP. Cell Counting Kit‑8 and TUNEL assays were conducted to detect cell viability and apoptosis. RT‑qPCR was employed to measure the expression levels of microRNA (miR)‑499a‑5p and STAT3. Western blotting was performed to measure the expression of STAT3 and apoptosis‑related proteins. Luciferase report assay was performed to verify the binding site between miR‑499a‑5p and STAT3. The production of inflammatory cytokines was determined using ELISA kits. The results exhibited the downregulated miR‑499a‑5p and dysregulated inflammatory cytokines in peripheral blood of patients and M. pneumoniae‑infected A549 cells. AZM and MP treatment alone or combined significantly inhibited inflammatory response, cell viability loss and promoted apoptosis in A549 cells infected with M. pneumoniae, which was partly reversed by inhibition of miR‑499a‑5p. Furthermore, miR‑499a‑5p could negatively regulate its direct target STAT3. In addition, STAT3 is also regulated by AZM and MP. Collectively, the present results suggested that combination treatment of AZM and MP could inhibit M. pneumoniae infection‑induced inflammation, cell viability loss and promoted apoptosis partly by regulating miR‑499a‑5p/STAT3 axis.

Related Articles

Journal Cover

September-2022
Volume 24 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Chen Y, Dong S, Tian L, Chen H, Chen J and He C: Combination of azithromycin and methylprednisolone alleviates <em>Mycoplasma pneumoniae</em> induced pneumonia by regulating miR‑499a‑5p/STAT3 axis. Exp Ther Med 24: 578, 2022
APA
Chen, Y., Dong, S., Tian, L., Chen, H., Chen, J., & He, C. (2022). Combination of azithromycin and methylprednisolone alleviates <em>Mycoplasma pneumoniae</em> induced pneumonia by regulating miR‑499a‑5p/STAT3 axis. Experimental and Therapeutic Medicine, 24, 578. https://doi.org/10.3892/etm.2022.11515
MLA
Chen, Y., Dong, S., Tian, L., Chen, H., Chen, J., He, C."Combination of azithromycin and methylprednisolone alleviates <em>Mycoplasma pneumoniae</em> induced pneumonia by regulating miR‑499a‑5p/STAT3 axis". Experimental and Therapeutic Medicine 24.3 (2022): 578.
Chicago
Chen, Y., Dong, S., Tian, L., Chen, H., Chen, J., He, C."Combination of azithromycin and methylprednisolone alleviates <em>Mycoplasma pneumoniae</em> induced pneumonia by regulating miR‑499a‑5p/STAT3 axis". Experimental and Therapeutic Medicine 24, no. 3 (2022): 578. https://doi.org/10.3892/etm.2022.11515